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D7-07 Novel therapeutics II, Thu, 12:30 - 14:15
A phase II NCCTG “Window of Opportunity Front-line” study 
of the mTOR Inhibitor, CCI-779 (Temsirolimus) given as a single 
agent in patients with advanced NSCLC 
Molina, Julian R.1 Mandrekar, Sumithra J.1 Rowland, Kendrith2 Reuter, 
Nicholas F.3 Jett, James R.1 Marks, Randolph1 Schild, Steven E.4 Adjei, 
Alex A.5 
1 Mayo Clinic, Rochester, MN, USA 2 NCCTG, Danville, USA 3 NCCTG, 
Sait Cloud, USA 4 Mayo Clinic Arizona, Scottsdale, AR, USA 5 Roswell 
Park Cancer Institute, Buffalo, NY, USA 
Background: Over-expression of Akt and loss of PTEN are frequent 
events in non-small cell lung cancer (NSCLC). The mammalian target 
of rapamycin (mTOR) is a protein downstream to Akt in the phosphati-
dylinositol 3-kinase (PI3K)/Akt signaling pathway. CCI-779 (temsi-
rolimus), an ester of sirolimus, is an inhibitor of mTOR with growth 
inhibitory activity in a variety of tumor cells. In an effort to evaluate 
the single agent activity of CCI-779 in previously untreated NSCLC, 
the NCCTG undertook a front-line “window of opportunity” study.
Methods: N0323 was a two-stage single arm phase II trial which 
evaluated the response and toxicity rates of CCI-779 administered as 
a front line single agent treatment for stage IIIB (pleural effusion) or 
IV NSCLC. Fresh tumor biopsies were obtain to evaluate predictive 
markers of CCI-779 activity and target inhibition such as phospho AKT 
expression and loss of PTEN. Patients received 25 mg of CCI-779 
administered intravenously as a 30 minute infusion on days 1, 8, 15, 
and 22 in4 week cycles. Based on a two-stage Fleming design with an 
exact signiﬁcance level of 0.05 and 94% power to detect an effec-
tive treatment if the true CRR was at least 20%, this treatment would 
be promising if at least 4 of the ﬁrst 25 evaluable patients in Stage I 
or at least 6 of the 50 evaluable patients at the end of Stage II have a 
conﬁrmed response. 
Results: A total of 55 patients were accrued from February 2004 to 
November 2006 and results from the ﬁrst 50 evaluable patients are 
reported here. Patient characteristics included a median age of 64 years 
(range: 44-85); 38% of patients were female; 84% had stage IV disease, 
and 89% were ECOG PS of 0 or 1. Median number of cycles adminis-
trated was 2 (range 1-18). One patient is still receiving active treatment 
(28 weeks). The most common grade 3/4 events were dyspnea (12%), 
fatigue (10%), hyperglycemia (8%), hypoxia (8%), nausea (8%), and 
rash/desquamation (6%). The clinical beneﬁt rate was 38% with 4 (8%: 
95% CI: 0.03-0.22) conﬁrmed partial responses and 15 (30%: 95% 
CI: 0.14-0.48) stable disease for a minimum of 56 days. The 24-week 
progression-free survival (PFS) rate was 22% (11/50; 95% CI: 0.12-
0.36). The median PFS and overall survival were respectively 2.3 and 
6.6 months. Sixteen (32%) patients received subsequent treatment after 
progressing on CCI-779. 
Conclusions: CCI-779 (Temsirolimus) given as a single agent front 
line therapy in patients with NSCLC produced a clinical beneﬁt rate of 
38% (8% PR, 30% SD). While the study did not meet the predeﬁned 
success criteria, single agent CCI-779 has activity similar to other 
signal transduction inhibitors and had good tolerability. Proper patient 
selection may enhance efﬁcacy. The potential predictive markers of 
efﬁcacy such as p70S-kinase phosphorylation and PTEN expression are 
being evaluated and these results will be presented.
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PD1-1-1 Epidemiology and Prevention & Early Detection, Mon, 16:00 - 17:30
Association between lung cancer incidence and family history of 
lung cancer
Nitadori, Jun-Ichi1 Inoue, Manami2 Iwasaki, Motoki2 Otani, Tetsuya2 
Sasazuki, Shizuka2 Nagai, Kanji1 Tsugane, Shoichiro2 
1 Thoracic Oncology Division, National Cancer Center Hospital East, 
Chiba, Japan 2 Epidemiology and Prevention Division, Center for Can-
cer Prevention and Screening, National Cancer Center, Tokyo, Japan 
Study Objectives: To clarify the possibility of a hereditary predisposi-
tion to lung cancer, we investigated the association between a family 
history of lung cancer and subsequent risk of lung cancer in a large-
scale, population-based cohort study.
Design: We investigated 102,255 middle-aged and older Japanese sub-
jects (48,834 men and 53,421 women) with 13-year follow-up. A total 
of 791 cases of lung cancer were newly diagnosed during the follow-up 
period. 
Results: A family history of lung cancer in a ﬁrst-degree relative was 
associated with a signiﬁcantly increased risk of lung cancer (hazard 
ratio [HR], 1.95; 95% conﬁdence interval [CI], 1.31 to 2.88). The 
association was stronger in women than in men (HR, 2.65; 95% CI, 
1.40 to 5.01 and HR, 1.69; 95% CI, 1.03 to 2.78, respectively), and in 
never-smokers than in current smokers (HR, 2.48; 95% CI, 1.27 to 4.84 
and HR, 1.73; 95% CI, 0.99 to 3.00, respectively). In addition, family 
history was more strongly associated with the risk of squamous cell 
carcinoma than with other histologic types (HR, 2.79; 95% CI, 1.37 to 
5.68), while no clear increase in risk was observed in adenocarcinoma 
and small cell carcinoma. A family history of overall cancer was not 
associated with an increased risk of lung cancer.
Conclusions: These results suggest that those with a family history of 
lung cancer are more likely to acquire lung cancer themselves.
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The significant influence of smoking status and gender on the 
clinical outcome in the patients with non-small cell lung cancer: a 
large-scale population based cohort study
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Background: To determine retrospectively whether smoking status 
and gender affect the treatment outcome and survival for the Japanese 
patients with non-small cell lung cancer. 
Methods: Using the database from the lung cancer registry of the 
National Hospital Study Group for Lung Cancer between 1987 and 
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2002, detailed demographic and survival information were obtained. A 
total of 18346 (70%)documented smokers including the former and the 
current and 7755(30%) documented never smokers with non-small cell 
lung cancer were studied. Among them, the 2546 patients with stage IV 
lung adenocarcinoma were studied to examine the relationship between 
the smoking status or the gender and the chemotherapy effect. Multi-
variate analysis was performed using the Cox regression method.
Results: There was an increased percentage of female subjects (72%) 
in the never smokers, and an increased percentage of male subjects 
(90%) in the smokers. The never smokers had lower performance 
status (PS) and lower clinical stage than the smokers (p<0.001). There 
was an increased percentage of adenocarcinoma (83%) in the never 
smokers. Multivariate analysis for all the patients demonstrated that 
the lower clinical stage, the lower PS, younger age, female and never 
smoking was an independent good prognostic factor The hazard ratio 
(HR) and its 95%CI was 3.73(3.58-3.88),2.69(2.59-2.79), 1.21(1.17-
1.25), 1.15(1.09-1.20), and 1.08(1.04-1.14), respectively. Multivariate 
analysis for the stage IV adenocarcinoma also showed that the lower 
PS, female and never smoking was an independent good prognostic 
factor. The HR and its 95%CI was 2.37(2.15-2.61), 1.35(1.19-1.52) 
and 1.17(1.04-1.32) respectively. In the treatment of chemotherapy for 
the stage IV adenocarcinoma patients, the never smokers had higher 
disease control rates (CR+PR+SD) than the smokers (p=0.08) and the 
females had higher response rates (CR+PR) than the males (p=0.02).
Conclusions: The never smokers and females with non-small cell lung 
cancer were found to have a distinct and improved clinical outcome.
PD1-1-3 Epidemiology and Prevention & Early Detection, Mon, 16:00 - 17:30
Trends of lung cancer incidence and mortality in Taiwan
Chien, Chun-Ru; Chen, Tony-Hsiu-Hsi 
Institute of Preventive Medicine, College of Public Health, National 
Taiwan University, Taipei, Taiwan
Background: In order to describe the recent lung cancer incidence & 
mortality in Taiwan, a Bayesian age-period-cohort (APC) model was 
applied 
Methods: Using the National Cancer Registry data from 1979 to 2002 
(n=91811), data from 1996 to 2002 with age at diagnosis between 20 
to 89 years old were used (n=44139) in view of data completeness 
(survival status & treatment strategies). An autoregressive prior model 
was used to smooth age, period, and cohort effects. Posterior distribu-
tions were derived from 5,000 iterations to draw inferences & 95% 
conﬁdence interval (95%CI). We deﬁned the median iterated value 
as an overall summary data. Age-adjusted standardized mortality & 
incidence rate (ASMR & ASIR, per 100000 person-year) and case 
fatality rate (ASMR/ASIR) were calculated using population in 2002 
as reference. Descriptive analysis was done for periodical treatment 
strategies distribution (operation, chemotherapy, & others) and related 
case fatality rate. 
Results: The mid-term mortality (2 year ASMR) was decreasing for 
male lung cancer patients in Taiwan since around year 2000 (from 48 
in 2000 to 45 in 2002), which was mainly due to decrease in incidence 
(ASIR) during this period (from 61 in 2000 to 57 in 2002). As for 
female, the mid-term (2 year) mortality was still slightly increasing 
(from 19 in 1996 to 22 in 2002), which was mainly due to increasing 
incidence (from 24 in 1996 to 29 in 2002). There were small improve-
ment in short term (1 year) case fatality rate, possibly due to Increased 
utilization (about 15~18% increment) of chemotherapy. The improve-
ment ranged from 68% (95%CI: 65-71) in 1997 to 65% (63-68) in 
2002 for male (ﬁg 1, upper) and 63% (59-67) in 1996 to 57% (54-60) 
in 2002 for female (ﬁg 1, lower). However, the mid term (2 year) case 
fatality rate roughly remained the same, especially for male (81% (95% 
CI 78-84) in 1997 to 82% (79-84) in 2002) (ﬁg 1, upper) in contrast to 
female (78%(74-83) in 1997 to 75(72-79) in 2002) (ﬁg 1, lower)
Conclusions: Mid-term mortality was decreasing for male lung cancer 
patients in Taiwan since around year 2000, while it was slightly increas-
ing for female. These changes were mainly due to change in incidence 
during this period. Increased utilization of chemotherapy may lead to 
small improvement in short term instead of mid term case fatality rate.
Figure 1. 1y: one year; 2y: two year; E: estimated case fatality rate; L & H: 95 % 
confidence interval
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Low socio-economic status is an independent poor prognostic 
factor for survival in stage I non-small-cell lung cancer, and is 
independent of marital status, race, and surgical treatment. A 
population-based analysis of 19,702 stage I NSCLC patients in the 
California Cancer Registry
Ou, Sai-Hong I.1 Zell, Jason A.1 Ziogas, Argyrios2 Anton-Culver, Hoda3 
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netic Epidemiology Research Institute, Irvine, CA, USA 3 Chao Family 
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Background: Certain racial minorities exhibit poor survival in early 
stage non-small cell lung cancer (NSCLC) in the US and is generally 
attributed to low socioeconomic status (SES). We investigated how the 
role SES may play a role in this disparity in survival.
Methods: We conducted a case-only analysis of the California Cancer 
Registry (CCR) (1989-2003) including descriptive analysis of relevant 
